• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

ACR Open Rheumatol . Development of a Prediction Model for COVID-19 Acute Respiratory Distress Syndrome in Patients With Rheumatic Diseases: Results

tetano

Editor, Senior Moderator
ACR Open Rheumatol


. 2022 Jul 22.
doi: 10.1002/acr2.11481. Online ahead of print.
Development of a Prediction Model for COVID-19 Acute Respiratory Distress Syndrome in Patients With Rheumatic Diseases: Results From the Global Rheumatology Alliance Registry


Zara Izadi[SUP] 1 [/SUP], Milena A Gianfrancesco[SUP] 1 [/SUP], Alfredo Aguirre[SUP] 1 [/SUP], Anja Strangfeld[SUP] 2 [/SUP], Elsa F Mateus[SUP] 3 [/SUP], Kimme L Hyrich[SUP] 4 [/SUP], Laure Gossec[SUP] 5 [/SUP], Loreto Carmona[SUP] 6 [/SUP], Saskia Lawson-Tovey[SUP] 7 [/SUP], Lianne Kearsley-Fleet[SUP] 8 [/SUP], Martin Schaefer[SUP] 9 [/SUP], Andrea M Seet[SUP] 1 [/SUP], Gabriela Schmajuk[SUP] 10 [/SUP], Lindsay Jacobsohn[SUP] 1 [/SUP], Patricia Katz[SUP] 1 [/SUP], Stephanie Rush[SUP] 1 [/SUP], Samar Al-Emadi[SUP] 11 [/SUP], Jeffrey A Sparks[SUP] 12 [/SUP], Tiffany Y-T Hsu[SUP] 12 [/SUP], Naomi J Patel[SUP] 13 [/SUP], Leanna Wise[SUP] 14 [/SUP], Emily Gilbert[SUP] 15 [/SUP], Alí Duarte-García[SUP] 16 [/SUP], Maria O Valenzuela-Almada[SUP] 16 [/SUP], Manuel F Ugarte-Gil[SUP] 17 [/SUP], Sandra Lúcia Euzébio Ribeiro[SUP] 18 [/SUP], Adriana de Oliveira Marinho[SUP] 19 [/SUP], Lilian David de Azevedo Valadares[SUP] 20 [/SUP], Daniela Di Giuseppe[SUP] 21 [/SUP], Rebecca Hasseli[SUP] 22 [/SUP], Jutta G Richter[SUP] 23 [/SUP], Alexander Pfeil[SUP] 24 [/SUP], Tim Schmeiser[SUP] 25 [/SUP], Carolina A Isnardi[SUP] 26 [/SUP], Alvaro A Reyes Torres[SUP] 27 [/SUP], Gelsomina Alle[SUP] 27 [/SUP], Verónica Saurit[SUP] 28 [/SUP], Anna Zanetti[SUP] 29 [/SUP], Greta Carrara[SUP] 29 [/SUP], Julien Labreuche[SUP] 30 [/SUP], Thomas Barnetche[SUP] 31 [/SUP], Muriel Herasse[SUP] 32 [/SUP], Samira Plassart[SUP] 32 [/SUP], Maria José Santos[SUP] 33 [/SUP], Ana Maria Rodrigues[SUP] 34 [/SUP], Philip C Robinson[SUP] 35 [/SUP], Pedro M Machado[SUP] 36 [/SUP], Emily Sirotich[SUP] 37 [/SUP], Jean W Liew[SUP] 38 [/SUP], Jonathan S Hausmann[SUP] 39 [/SUP], Paul Sufka[SUP] 40 [/SUP], Rebecca Grainger[SUP] 41 [/SUP], Suleman Bhana[SUP] 42 [/SUP], Wendy Costello[SUP] 43 [/SUP], Zachary S Wallace[SUP] 13 [/SUP], Jinoos Yazdany[SUP] 1 [/SUP], Global Rheumatology Alliance Registry



Affiliations

Abstract

Objective: Some patients with rheumatic diseases might be at higher risk for coronavirus disease 2019 (COVID-19) acute respiratory distress syndrome (ARDS). We aimed to develop a prediction model for COVID-19 ARDS in this population and to create a simple risk score calculator for use in clinical settings.
Methods: Data were derived from the COVID-19 Global Rheumatology Alliance Registry from March 24, 2020, to May 12, 2021. Seven machine learning classifiers were trained on ARDS outcomes using 83 variables obtained at COVID-19 diagnosis. Predictive performance was assessed in a US test set and was validated in patients from four countries with independent registries using area under the curve (AUC), accuracy, sensitivity, and specificity. A simple risk score calculator was developed using a regression model incorporating the most influential predictors from the best performing classifier.
Results: The study included 8633 patients from 74 countries, of whom 523 (6%) had ARDS. Gradient boosting had the highest mean AUC (0.78; 95% confidence interval [CI]: 0.67-0.88) and was considered the top performing classifier. Ten predictors were identified as key risk factors and were included in a regression model. The regression model that predicted ARDS with 71% (95% CI: 61%-83%) sensitivity in the test set, and with sensitivities ranging from 61% to 80% in countries with independent registries, was used to develop the risk score calculator.
Conclusion: We were able to predict ARDS with good sensitivity using information readily available at COVID-19 diagnosis. The proposed risk score calculator has the potential to guide risk stratification for treatments, such as monoclonal antibodies, that have potential to reduce COVID-19 disease progression.
 
Back
Top Bottom